Following U.S. Stocks are among the “Most Active” Stocks in the course of recent trading session, Wednesday: General Electric (NYSE:GE), Freeport-McMoRan (NYSE:FCX) , Vascular Biogenics (NASDAQ:VBLT), Whiting Petroleum (NYSE:WLL)
TransData, Inc., received notice that the U.S. Patent and Trademark Office (“Patent Office”) concluded an ex parte reexamination of TransData’s U.S. Patent No. 6,181,294 (the ‘294 Patent) and will issue a Reexamination Certificate that reaffirms validity of all pending claims. This decision by the Patent Office marks another victory by TransData over the serial patent reexaminations being filed against the company’s Smart Meter Patents by General Electric Company (GE). TransData’s ‘294 patent has now withstood several patent reexaminations filed by General Electric and another smart meter manufacturer.
General Electric Company (NYSE:GE) decreased -0.32%, and is now trading at $25.18. The company holds the market capitalization of $253.60 B. For the last twelve months, the stock was able to keep return on equity at 13.80%, while return on assets at 2.80%, in response to its return on investment at 3.40%. Its 20-day moving average decreased -1.56%, above 50-day moving average of 1.52%, below 200-day moving average of -0.11% from the latest market price of $25.18. The mean recommendation of analysts for this stock is 2.20. (Where 1=Buy, 5=Sale).
General Electric Company (GE) operates as an infrastructure and financial services company worldwide. The company’s Power and Water segment offers gas, steam and aeroderivative turbines, nuclear reactors, generators, combined cycle systems, controls, and related services; wind turbines; and water treatment services and equipment. Its Oil and Gas segment provides surface and subsea drilling and production systems, equipment for floating production platforms, compressors, turbines, turboexpanders, reactors, industrial power generation, and auxiliary equipment.
Freeport-McMoRan Inc (NYSE:FCX), declared that it has declared a cash dividend of $0.05 per share payable on May 1, 2015 to holders of record as of April 15, 2015 for its ordinary stock.
James R. Moffett, Chairman of the Board; Richard C. Adkerson, Vice Chairman, and FCX President and Chief Executive Officer; and James C. Flores, Vice Chairman, and FM O&G President and Chief Executive Officer, said, “The reduction in the dividend is a prudent measure to strengthen our balance sheet during a period of volatile market conditions. As formerly declared, our plans comprise noteworthy reductions in capital spending and other costs and we are evaluating funding opportunities for capital expenditures in our oil and gas business. We will continue to take steps to enhance our financial position and to preserve our high quality resources for improved market conditions in the future. We are optimistic about our business, long-term commodity markets and the noteworthy values embedded in our large-scale, long-lived assets. We are committed to achieving our plans to raise production volumes and to prudently manage capital spending which will enable us to reduce debt over time and raise future returns to shareholders.”
Freeport-McMoRan Inc (NYSE:FCX) inclined 0.36%, and is now trading at $19.25. The company has the market capitalization of $20.04 billion. The beta value of the stock is 2.25. On the other hand the stock’s volatility for the week is 6.38%, and for the month is 4.21%. The stock’s price to book ratio is $1.09, however price to sale ratio is $0.93. Analyst’s mean recommendation regarding this stock is 2.40. (Where 1=Buy, 5=Sale).
Freeport-McMoRan Inc (FCX) a natural resource company engages in the acquisition of mineral assets, and oil and natural gas resources. It primarily explores for copper, gold, molybdenum, cobalt, silver, and other metals, as well as oil and gas. The company operates through North America Copper Mines; South America Mining; Indonesia Mining; Africa Mining; Molybdenum Mines; United States (U.S.) Oil and Gas Operations; Rod & Refining; and Atlantic Copper Smelting & Refining segments.
Vascular Biogenics Ltd (NASDAQ:VBLT), declared top-line interim results from its ongoing Phase 2 study of VB-111 in patients with recurrent glioblastoma (rGBM), which demonstrated a statistically noteworthy improvement in overall survival in patients treated with VB-111 followed by VB-111 in combination with bevacizumab (Avastin(R)) upon disease progression, contrast to patients treated with VB-111 followed by bevacizumab alone upon disease progression (p=0.05). Study results will be presented in conjunction with the American Society of Cancer Oncology (ASCO) Annual Meeting, May 29th-June 2nd, 2015 in Chicago, Illinois.
Vascular Biogenics Ltd (NASDAQ:VBLT) raised 28.01%, and is now trading at $7.15.Price to book ratio is 2.90. With recent incline, the year-to-date (YTD) performance reflected a 24.2% incline above last year. During the past month the stocks gain 78.16%, bringing three-month performance to 22.33% and six-month performance to -34.17%. The mean recommendation of analysts for this stock is 2.70 (where 1=Buy, 5=Sale).
Vascular Biogenics Ltd (VBLT) a clinical-stage biopharmaceutical company, is engaged in the discovery, development, and commercialization of treatments for cancer and immune-inflammatory diseases. Its lead product candidates include VB-111, a gene-based biologic, which is in Phase II clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer; in Phase II clinical trials to treat thyroid cancer; and in Phase I/II clinical trials for the treatment of ovarian cancer, as well as VB-201, an oral small molecule that is in Phase II clinical trials for the treatment psoriasis and ulcerative colitis.
Whiting Petroleum Corp (NYSE:WLL), declared that it has priced $750 million aggregate principal amount of 6.25% senior notes due 2023 in a private unregistered offering to eligible purchasers. The notes were priced at par. The offering is predictable to close on March 27, 2015, subject to customary conditions.
Whiting formerly declared that it had priced a public offering of 35,000,000 shares of its ordinary stock for total net proceeds of about $1.0 billion, after deducting underwriter’s discounts and commissions. The underwriter in that offering has a 30-day option to purchase up to an additional 5,250,000 shares of Whiting’s ordinary stock. Whiting also formerly declared that it had priced a private unregistered offering of $1.0 billion aggregate principal amount of 1.25% convertible senior notes due 2020. The initial purchasers in that offering have a 30-day option to purchase up to an additional $250.0 million aggregate principal amount of convertible senior notes.
Whiting Petroleum Corp (NYSE:WLL) shares picked up 0.06%, and is now trading at $30.93. The stock volatility for the week is 6.41%, while for the month remained 6.15%. The company holds consensus target price of $45.97.
If we consider EPS growth of the company, then the company indicated the following observations:
The company showed 0.80 diluted EPS growth for trailing twelve months. However, YTD EPS growth remained -82.70% and Annual EPS growth for the past 5 years is considered as 19.60%.
The mean recommendation of analysts for this stock is 2.10. (Where 1=Buy, 5=Sale).
Whiting Petroleum Corp (WLL) an independent oil and gas company, acquires, explores, develops, and produces crude oil, natural gas liquids, and natural gas in the Rocky Mountains and Permian Basin regions of the United States. It sells oil and gas to end users, marketers, and other purchasers. As of December 31, 2014, the companys estimated proved reserves totaled 780.3 million barrels of oil equivalent; and had interests in 4,471 net productive wells across approximately 886,700 net developed acres.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The data demonstrated in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
